Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 6Phase 1 4Phase 1/2 3Phase EARLY_PHASE1 1Phase 4 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 2Inflammatory Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × trastuzumab biosimilar HLX02 × Breast × Clear all
NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 15 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
2 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡